Top Stem Cell Stocks 2012/2013 - Pluristem Therapeutics, Inc. (PSTI)
- Pluristem Therapeutics, Inc. (PSTI) is the top stem cell stock right now in 2012 as the company continues to release positive
news on clinical trials. Pluristem Therapeutics, Inc. (PSTI) stock is currently trading at $4.25, Up 68% in 2012.
Please note that PSTI is a stock to buy for the future as they will need a lot of capital to survive. This small
cap biotech company might not be able to bring a drug to market until 2019 or 2020.
Inc. (PSTI) a bio-therapeutic company, engages in the research, development, and commercialization of standardized cell therapy
products for the treatment of life threatening diseases. The companys products are derived from human placenta, a non-controversial,
non-embryonic, adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional
process that allows cells to grow in a natural environment. The company provides PLX-PAD that has completed Phase I clinical
trials for people suffering from peripheral artery disease. It also offers various product candidates for diabetic foot ulcers,
adjuvant hip replacement surgery, athletic injuries, inflammatory bowel disease, multiple sclerosis, neuropathic pain, ischemic
stroke, adjuvant for UCB transplantation, and radiation exposure.
Best Stem Cell Stocks 2013 - StemCells Inc. (STEM) - StemCells
Inc. (STEM) is a stock I have been trading during the summer of 2012 in the stock picks group. STEM is a $2 stock that has doubled over the past three months due to several $20 million grants and positive clinical
trial data. I feel that if STEM continues to report good news, this stem cell stock is a great buy. StemCells,
Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease Program.
(STEM) Price Target 2013 - $4 - STEM is a great stem cells stock to buy if you are looking for a high risk penny stock.
StemCells, Inc., a biopharmaceutical company,
engages in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies
for academia and industry. It develops cell-based therapeutics for the central nervous system and liver. The companys
product candidate HuCNS-SC cells has completed a Phase I clinical trial for the treatment of infantile and late infantile
neuronal ceroid lipofuscinosis, a neurodegenerative disorder of the brain; and completed a Phase I clinical trial for the
treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. It also engages in developing HuCNS-SC
cells, which are in Phase I/II clinical trial for the treatment of chronic spinal cord injury; and HuCNS-SC cells that are
in Phase I/II clinical trial for the treatment of dry age-related macular degeneration. In addition, the company identifies
and develops human liver engrafting cells for a range of liver diseases; and is involved in developing and commercializing
applications of its technologies to enable stem cell-based research.